An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke: gender-dependent effect

ObjectivesMinocycline as an antibiotic has been found to have neuroprotective effect on neurodegenerative diseases. This study was aimed at determining the efficacy of minocycline adjunct to aspirin in improving neurological outcomes of ischemic stroke during 3-month follow-up. Methods and materialsIn an open-label evaluator-blinded trial, 60 patients with ischemic stroke were allocated into two groups to receive either 200mg of oral minocycline daily for 5days during 6-24h following onset of signs and symptoms, or not receiving any, as control; all patients also received 100mg of aspirin daily. Clinical assessment at baseline and on days 30, 60, and 90 was performed using National Institutes of Health Stroke Scale (NIHSS) score. ResultsFifty-three patients (88.3%) completed the study. Females in the treatment and control groups were 53.8% and 51.9%, respectively (P=0.884). Among all patients, NIHSS score was significantly lower in the minocycline-treated compared with control on day 90 (minocycline median 4, interquartile range 4-7, control median 7, interquartile range 5-8, P=0.031). Among males, NIHSS was lower in minocycline-treated compared with controls on days 30, 60, and 90 (P<0.05); however, females showed no significant differences at the same times compared with controls. No adverse outcomes including myocardial infarction, recurrent stroke, and mortality were observed in the both groups. ConclusionPatients with ischemic stroke who received oral minocycline daily for 5days had significantly better neurological outcomes on day 90 than controls. However, females showed no significant clinical improvement compared to males.